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Objective. Standard treatment for severe granulomatosis with polyangiitis (Wegener’s) (GPA) is daily oral cyclophos-
phamide (CYC), a cytotoxic agent associated with ovarian failure. In this study, we assessed the rate of diminished
ovarian reserve in women with GPA who received CYC versus methotrexate (MTX).
Methods. Patients in the Wegener’s Granulomatosis Etanercept Trial received either daily CYC or weekly MTX and were
randomized to etanercept or placebo. For all women ages <50 years, plasma samples taken at baseline or early in the
study were evaluated against samples taken later in the study to compare levels of anti-Mu¨llerian hormone (AMH) and
follicle-stimulating hormone (FSH), endocrine markers of remaining egg supply. Diminished ovarian reserve was deﬁned
as an AMH level of <1.0 ng/ml.
Results. Of 42 women in this analysis (mean age 35 years), 24 had CYC exposure prior to enrollment and 28 received the
drug during the study. At study entry, women with prior CYC exposure had signiﬁcantly lower AMH, higher FSH, and
a higher rate of early menstruation cessation. For women with normal baseline ovarian function, 6 of 8 who received CYC
during the trial developed diminished ovarian reserve, compared to 0 of 4 who did not receive CYC (P < 0.05). Changes
in AMH correlated inversely with cumulative CYC dose (P < 0.01), with a 0.74 ng/ml decline in AMH level for each 10
gm of CYC.
Conclusion. Daily oral CYC, even when administered for less than 6 months, causes diminished ovarian reserve, as
indicated by low AMH levels. These data highlight the need for alternative treatments for GPA in women of childbearing
age.
Introduction
Among women treated with cyclophosphamide (CYC),
ovarian failure has long been viewed as an unfortunate but
inevitable consequence of therapy. However, with recent
successes in ovarian preservation and new alternative
therapies for vasculitis, patients with this condition may
now be able to avoid this treatment complication. Al-
though the frequency of ovarian failure following CYC
therapy in patients with vasculitis has not been previouslyClinicalTrials.gov identiﬁer: NCT00005007.
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assessed, reports have suggested that 30–50% of women
receiving intravenous monthly CYC for other indications
develop ovarian failure (1,2). We suspected that the rate of
ovarian dysfunction might be higher for women receiving
daily oral CYC, the standard treatment protocol for vas-
culitis, as this method of administration exposes the ovary
to toxic therapy daily and leads to cumulative doses 2–3-
fold higher than those resulting from the monthly intrave-
nous doses typically administered for other conditions.
In prior studies, ovarian failure has been determined
according to 2 criteria: the cessation of menstruation and
elevated levels of follicle-stimulating hormone (FSH).
While these measures accurately identify women in meno-
pause, they are less useful for assessing whether a woman
has compromised fertility. Even in healthy women, fertil-
ity signiﬁcantly declines in the 2 decades prior to meno-
pause, when menstruation is still active and FSH levels are
in the normal range (3). Using only the presence of menses
and high FSH levels to evaluate ovarian function therefore
underestimates the number of women with ovarian dam-
age that can limit fertility and hasten menopause.
Anti–Mu¨llerian hormone (AMH) is a newer marker that
better reﬂects ovarian reserve and can predict the time to
menopause. Produced by small early follicles whose on-
going growth is independent of the menstrual cycle, AMH
by extension reﬂects the number of primordial follicles
that remain in the ovary (4). AMH provides several notable
advantages over more traditional measures of ovarian
function: 1) exhibiting little ﬂuctuation between or within
menstrual cycles, AMH can be measured at any time in
the cycle (5); 2) in healthy patients, AMH levels decline
slowly with aging, but among women who sustain ovarian
injury from chemotherapy or radiation, these levels de-
cline more rapidly (6); 3) on average, a 40-year-old woman
will have an AMH level of 1.0 ng/ml (7), and as AMH
levels decline below this, conception becomes less likely
(but not impossible); and 4) the decline in AMH precedes
the rise in FSH and menopause by several years (8).
To our knowledge, this is the ﬁrst study of AMH in
women with vasculitis. By comparing female vasculitis
patients who have undergone CYC therapy with those who
have not, we have been able to investigate the impact of
this therapy on AMH and therefore to assess associated
subclinical ovarian damage and diminished ovarian re-
serve.
Patients and Methods
The Wegener’s Granulomatosis Etanercept Trial (WGET)
was a randomized, double-blind, placebo-controlled trial
of etanercept, a tumor necrosis factor  inhibitor, for the
treatment of granulomatosis with polyangiitis (Wegener’s)
(GPA). The study design and main results have been de-
scribed in detail in an earlier publication (9).
In addition to receiving twice-weekly subcutaneous in-
jections of etanercept in 25 mg doses or placebo, all of the
patients also underwent standard therapy for active GPA.
Patients with severe disease received prednisone and daily
oral CYC at a dosage of 2 mg/kg/day, with adjustments for
renal insufﬁciency. Patients who presented with limited
disease received prednisone and methotrexate (MTX) in
increasing weekly oral doses of up to 25 mg. Patients with
renal dysfunction received azathioprine instead of MTX.
For patients who experienced severe GPA ﬂares during the
trial, therapy with CYC and glucocorticoids was initiated.
Women were also allowed to take oral contraceptives,
depot medroxyprogesterone, or gonadotropin-releasing
hormone (GnRH) agonists.
For this subanalysis of the WGET data set, we included
all women who were ages 50 years at the time of enroll-
ment. Two time points for analysis were included for each
qualiﬁed patient: the ﬁrst available plasma sample (taken
either at screening or at an early followup visit) and the
last available plasma sample. After collection, the plasma
samples were delivered to the University of North Carolina
Immunotechnologies Core for enzyme-linked immunosor-
bent assay, where AMH and FSH were measured.
Diminished ovarian reserve was deﬁned as an AMH
level of 1.0 ng/ml. For purposes of baseline analysis,
patients were divided by age:18 years, when AMH tends
to be on the increase; 18–35 years, during which years
AMH tends to decline slowly; and 35 years, when AMH
is expected to approach 1.0 ng/ml.
FSH is most reliable as a predictor of ovarian function
when blood samples are drawn early in the menstrual
cycle. In this study, however, blood draws were not timed
with menses, which diminished the usefulness of FSH in
assessing ovarian sufﬁciency. In addition, oral contracep-
tives and GnRH agonists suppress FSH, so all women
receiving these medications were excluded from the FSH
analysis. Menstrual history was only obtained at study
entry.
We assessed 4 primary outcomes. First, we compared
the proportion of women with diminished ovarian reserve
at study entry and completion based on prior CYC expo-
sure. To evaluate the effect of CYC on AMH during the
trial, we included only women with a baseline AMH level
1.0 ng/ml. To determine the dose effect of CYC on AMH,
we employed regression analysis, with a P value of less
than 0.05 being considered statistically signiﬁcant. Fi-
nally, women were divided by age to assess the role that
age at CYC therapy has on ovarian function.
Signiﬁcance & Innovations
● This study demonstrates that even low doses of
daily oral cyclophosphamide can have a clinically
signiﬁcant and lasting impact on ovarian reserve
in women with vasculitis.
● The effect of cyclophosphamide on ovarian re-
serve in women with vasculitis had not previously
been assessed. The data from systemic lupus ery-
thematosus (SLE) patients treated with cyclophos-
phamide cannot reliably be applied to patients
with vasculitis, given the difference in dosing
methods (intermittent intravenous for SLE pa-
tients versus daily oral for vasculitis patients).
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Results
Of the 180 total patients enrolled in the study, 42 were
women ages 50 years at trial entry. Two of these women
were excluded from the analysis of baseline hormone lev-
els, as no sample had been taken for them prior to the
administration of CYC during the trial. Therefore, 40
women qualiﬁed for the baseline analysis, with a mean 
SD age of 35.2  9.2 years (range 14–46 years). The ma-
jority were white (86%), educated beyond high school
(64%), and either employed or in school (64%).
The patients’ baseline AMH concentrations were highly
dependent on both age and prior CYC therapy (Table 1). Of
40 patients, 24 (60%) had received CYC prior to the ﬁrst
available hormone sample. For women between ages 18
and 35 years, the mean AMH concentration was 4-fold
higher and the rate of diminished ovarian reserve signiﬁ-
cantly was lower among women who had not received
prior CYC (P  0.01). For women ages 35 years, a trend
toward diminished AMH among those with prior CYC
therapy was evident, but not statistically signiﬁcant. Pre-
mature cessation of menstruation occurred predominantly
in women ages 35 years with prior CYC exposure. FSH
was almost 4-fold higher for women with prior CYC expo-
sure, but the differences were not statistically signiﬁcant
based on age.
Only 12 women entered the study with normal ovarian
reserve. In this group, those treated with CYC during the
WGET experienced a decline in AMH levels signiﬁcantly
greater than that experienced by women who did not re-
ceive CYC (Figure 1). The 8 women who received CYC had
a mean  SD decline in AMH from 4.2  2.3 ng/ml to
0.6  0.5 ng/ml. The 4 women who did not receive CYC
registered a modest increase in their mean  SD AMH
concentrations, from 3.3  1.0 ng/ml to 4.0 1.4 ng/ml
(P  0.005, comparing the change in women exposed
versus not exposed to CYC). Of these 4 women, 3 were
adults whose AMH levels remained steady; one young
patient’s AMH levels rose as she went through puberty.
The degree of change in AMH level was predicted by the
cumulative dose of CYC administered during the trial (re-
Table 1. Menstruation and hormone levels at the ﬁrst available sample*
Women ages
<50 years
No CYC prior to
WGET enrollment (n)
CYC prior to WGET
enrollment (n) P
AMH level at ﬁrst sample,
mean  SD ng/ml
All patients 1.4  2.0 2.5  2.4 (16) 0.6  1.2 (24) 0.002
Age 18 years 1.6  1.8 0.67 (1) 2.0  2.3 (2) NA†
Age 18–35 years 2.5  2.4 4.2  1.9 (7) 1.0  1.7 (8) 0.004
Age 35 years 0.6  1.2 1.1  1.9 (8) 0.3  0.4 (14) 0.14
Diminished ovarian reserve
(AMH level 1.0 ng/ml), %
All patients 70 50 (16) 83 (24) 0.03
Age 18 years 67 100 (1) 50 (2) NA†
Age 18–35 years 40 0 (7) 75 (8) 0.003
Age 35 years 91 86 (8) 93 (14) 0.6
Premature cessation of
menstruation, %
All patients 21 0 (16) 33 (24) 0.013
Age 18 years 0 0 (1) 0 (2) NA†
Age 18–35 years 6 0 (7) 13 (8) 0.32
Age 35 years 36 0 (8) 50 (14) 0.015
Baseline FSH by age group,
mean  SD mIU/ml‡
All patients 14.9  20.9 5.3  7.6 (12) 20.63  24.2 (20) 0.042
Age 18 years 4.4 4.4 (1) – NA†
Age 18–35 years 8.2  11.1 2.2  2.0 (4) 11.67  12.9 (7) 0.19
Age 35 years 19.1  24.4 7.2  9.7 (7) 25.45  27.8 (13) 0.11
* CYC  cyclophosphamide; WGET  Wegener’s Granulomatosis Etanercept Trial; AMH  anti-Mu¨llerian hormone;
NA  not applicable; FSH  follicle-stimulating hormone.
† Too few subjects for reliable statistical testing.
‡ FSH analysis does not include women currently taking oral contraceptives or gonadotropin-releasing hormone
agonists.
Figure 1. Change in anti-Mu¨llerian hormone (AMH) during the
Wegener’s Granulomatosis Etanercept Trial (WGET) for women
with a baseline AMH level of 1.0 ng/ml. Red lines show cyclo-
phosphamide (CYC) received during the WGET. Blue lines show
those that did not receive CYC during the WGET.
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gression coefﬁcient 0.074, P  0.01). For each 10 gm of
CYC administered, the AMH level fell, on average, by 0.74
ng/ml (Figure 2). Adjusting for age at study entry did not
impact the statistical signiﬁcance of the correlation be-
tween cumulative CYC dose and decline in AMH. The
AMH level of 2 women increased modestly (by 0.59 and
0.83 ng/ml) 3 years after CYC cessation. This study was not
powered to identify other risk factors for AMH decline.
Every dose level of CYC appeared to signiﬁcantly de-
crease AMH in this study. Even the 3 women ages 35
years who received 12.5 gm of CYC prior to study entry
had a baseline AMH level lower than expected for their
age (range 0.47–1.03 ng/ml for women ages 23–32 years).
Of 10 women ages 35 years who received 12.5–25 gm of
CYC, only 2 exited the study with AMH levels1.0 ng/ml.
These data suggest that most, but not all, women treated
with a short course of daily oral CYC sustain signiﬁcant
ovarian damage.
Discussion
This study documents the rapid ovarian damage caused by
oral CYC in women ages50 years who undergo treatment
for GPA. At baseline, women with prior CYC therapy had
signiﬁcantly lower AMH, higher FSH, and a higher rate of
diminished ovarian reserve, and were more likely to have
premature cessation of menses. Regardless of their base-
line measures, all women ages50 years treated with CYC
during the trial experienced a dramatic decrease in AMH.
The cumulative dose of CYC was directly correlated to the
degree of this decline, but even a low cumulative dose over
a short duration was associated with unusually low AMH.
Although previous studies of women with rheumatic
disease have likewise documented ovarian failure follow-
ing treatment with CYC, these studies employed cessation
of menses and elevated FSH as the only indicators. Using
this deﬁnition, an estimated 30% of women with systemic
lupus erythematosus will develop ovarian failure follow-
ing CYC, with older age and higher cumulative CYC dose
as the most important predictors.
Although the average age of women at menopause is
51 years, the average age of last childbirth in societies that
do not use contraception is 41 years, which indicates that
menstrual bleeding persists for an average of 10 years in
the absence of ovarian function capable of producing
pregnancy (3). Determining ovarian function based on
menses therefore fails to provide sufﬁcient information
about fertility.
AMH, a marker of ovarian reserve primarily studied in
the reproductive endocrinology literature, has now also
gained favor in the chemotherapy literature based on its
improved sensitivity proﬁle relative to traditional FSH
testing. In females, AMH is low at birth, rises during late
puberty, then declines with age, becoming undetectable
after both natural and surgical menopause (7). Unlike FSH,
AMH does not ﬂuctuate signiﬁcantly throughout the men-
strual cycle (5). Moreover, according to numerous obser-
vational studies of the effects of chemotherapy, decre-
ments in AMH precede elevations in FSH (10).
Whether AMH levels could rebound to a clinically sig-
niﬁcant degree over a long period of time following ad-
ministration of CYC is not known. In this cohort, AMH
level was found to have increased by 0.5–0.8 ng/ml in
2 women with 3 years of post-CYC followup. Anecdotal
evidence suggests that women with apparent infertility for
years to decades following CYC therapy may eventually
conceive naturally. It cannot be determined, however, if
this reﬂects a slow rise in AMH and ovarian viability, or
if it reﬂects that while egg number is low, individual egg
quality can still provide for the fortuitous happenstance
that one of the remaining oocytes will be fertilized.
Unfortunately, this study does not provide sufﬁcient
data to determine the impact of oral contraceptives or
GnRH agonists on ovarian preservation. Most prior studies
of oral contraceptives during CYC therapy have not docu-
mented a protective effect (11). GnRH agonist cotherapy
during CYC treatment, however, has been shown to pre-
vent cessation of menstruation in both rheumatologic and
oncologic studies (12). How this protocol might affect fer-
tility or AMH is less clear.
The dramatic decline in ovarian reserve with CYC ther-
apy documented in this study suggests that physicians
should consider alternate therapies for young women with
vasculitis. Several options exist, including administration
of intermittent intravenous rather than daily oral CYC,
using the shortest course of CYC possible then switching
to a medication that is less toxic to the ovaries, and con-
sideration of rituximab therapy for young women (13). The
Rituximab in ANCA (antineutrophil cytoplasmic anti-
body)–Associated Vasculitis trial recently demonstrated
that rituximab may be a viable option for young women
who wish to preserve fertility but require treatment of
ANCA-associated vasculitis (14). Other avenues for fertil-
ity preservation include cotherapy with GnRH agonists
and cryopreservation of the ovary, oocytes, or embryos.
Access to a control group with GPA (although not of
similar severity), use of a single ovarian toxic medication,
Figure 2. Change in anti-Mu¨llerian hormone (AMH; ng/ml) level
by cumulative cyclophosphamide dose (mg) during the Wegener’s
Granulomatosis Etanercept Trial. This analysis included only
women with a baseline AMH level of 1.0 ng/ml.
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and use of AMH as a marker of subclinical ovarian damage
confer particular importance on the results of this study.
The primary drawbacks lie in the limited number of
women without previous CYC exposure and the fact that
this analysis was not planned prior to enrollment in
WGET; as a result, blood draws were not timed to the
menstrual cycle, therefore making the FSH measurement
less useful, and menstrual histories were not taken at the
completion of the study. Due to the difference in primary
outcome, these lapses have prevented direct comparison
of the current study to other investigations of ovarian
function in women with rheumatic disease.
Nevertheless, this study strongly suggests that the ad-
ministration of daily oral CYC for severe GPA results in
ovarian damage among women of childbearing age. Efforts
to minimize ovarian exposure to CYC may therefore help
preserve fertility and delay menopause in women with
vasculitis.
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